Nektar Therapeutics (NKTR)
(Delayed Data from NSDQ)
$1.24 USD
+0.06 (5.08%)
Updated Sep 10, 2024 04:00 PM ET
After-Market: $1.23 -0.01 (-0.81%) 6:42 PM ET
3-Hold of 5 3
D Value D Growth F Momentum F VGM
Company Summary
San Francisco, CA-based Nektar Therapeutics is a biopharmaceutical company, focused on the development of treatments utilizing its PEGylation and advanced polymer conjugate technology platforms.
Nektar primarily finances its operations with funds from licensing, collaboration and manufacturing agreements. It has collaboration deals with companies namely AstraZeneca, Roche and Amgen among others.
Nektar recognizes product sales from its manufacturing and supply agreements with several pharma companies related to products developed using its PEGylation platform. The company also earns royalty payments from the sales of products using its technology ...
Company Summary
San Francisco, CA-based Nektar Therapeutics is a biopharmaceutical company, focused on the development of treatments utilizing its PEGylation and advanced polymer conjugate technology platforms.
Nektar primarily finances its operations with funds from licensing, collaboration and manufacturing agreements. It has collaboration deals with companies namely AstraZeneca, Roche and Amgen among others.
Nektar recognizes product sales from its manufacturing and supply agreements with several pharma companies related to products developed using its PEGylation platform. The company also earns royalty payments from the sales of products using its technology platforms. Amgen’s neutropenia drug, Neulasta is one of the drugs developed using Nektar’s PEGylation platform.
Nektar has two key candidates in its clinical pipeline, rezpegaldesleukin (rezpeg) and NKTR-255. The company regained full rights to rezpeg from Eli Lily in April 2023, and is now in charge of its clinical development. Rezpeg has become a wholly-owned asset of Nektar. NKTR-255 is developed as a cell therapy enhancer to boost the anti-tumor immune response of other cancer therapies, especially CAR T therapies.
The company’s pipeline candidate, bempegaldesleukin (bempeg), failed in three late-stage registrational studies in the first quarter of 2022. Following these failures, Nektar stopped all clinical studies on bempeg in early 2022. The candidate was being developed in collaboration with Bristol Myers.
However, following the discontinuation of bempeg development, Nektar terminated its collaboration agreement with Bristol Myers and is not eligible to receive any payments from the latter.
Nektar generated total revenues of $90.1 million in 2023, down from $92.1 million in 2022.
General Information
Nektar Therapeutics
455 MISSION BAY BOULEVARD SOUTH
SAN FRANCISCO, CA 94158
Phone: 415-482-5300
Fax: 415-339-5300
Email: investors@nektar.com
Industry | Medical - Drugs |
Sector | Medical |
Fiscal Year End | December |
Last Reported Quarter | 6/30/2024 |
Exp Earnings Date | 11/5/2024 |
EPS Information
Current Quarter EPS Consensus Estimate | -0.23 |
Current Year EPS Consensus Estimate | -0.85 |
Estimated Long-Term EPS Growth Rate | NA |
Exp Earnings Date | 11/5/2024 |
Price and Volume Information
Zacks Rank | ![]() |
Yesterday's Close | 1.18 |
52 Week High | 1.93 |
52 Week Low | 0.41 |
Beta | 0.60 |
20 Day Moving Average | 816,896.62 |
Target Price Consensus | 1.30 |
4 Week | 6.31 |
12 Week | 0.85 |
YTD | 108.85 |
4 Week | 3.85 |
12 Week | 0.89 |
YTD | 82.08 |
Shares Outstanding (millions) | 184.08 |
Market Capitalization (millions) | 217.21 |
Short Ratio | NA |
Last Split Date | 8/23/2000 |
Dividend Yield | 0.00% |
Annual Dividend | $0.00 |
Payout Ratio | NA |
Change in Payout Ratio | NA |
Last Dividend Payout / Amount | NA / $0.00 |
Fundamental Ratios
P/E (F1) | NA |
Trailing 12 Months | NA |
PEG Ratio | NA |
vs. Previous Year | 7.41% |
vs. Previous Quarter | -38.89% |
vs. Previous Year | 14.59% |
vs. Previous Quarter | 8.55% |
Price/Book | 2.72 |
Price/Cash Flow | NA |
Price / Sales | 2.33 |
6/30/24 | -133.64 |
3/31/24 | -107.31 |
12/31/23 | -96.80 |
6/30/24 | -42.03 |
3/31/24 | -38.08 |
12/31/23 | -37.17 |
6/30/24 | 5.15 |
3/31/24 | 6.10 |
12/31/23 | 6.45 |
6/30/24 | 4.90 |
3/31/24 | 5.79 |
12/31/23 | 6.14 |
6/30/24 | -178.16 |
3/31/24 | -182.69 |
12/31/23 | -195.53 |
6/30/24 | -190.09 |
3/31/24 | -195.02 |
12/31/23 | -306.31 |
6/30/24 | -190.17 |
3/31/24 | -195.21 |
12/31/23 | -306.54 |
6/30/24 | 0.43 |
3/31/24 | 0.69 |
12/31/23 | 0.69 |
6/30/24 | 2.45 |
3/31/24 | 2.07 |
12/31/23 | 1.87 |
6/30/24 | 0.00 |
3/31/24 | 0.00 |
12/31/23 | 0.00 |
6/30/24 | 0.00 |
3/31/24 | 0.00 |
12/31/23 | 0.00 |